Abiraterone Acetate Combined With Dutasteride for Metastatic Castrate Resistant Prostate Cancer

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

40 participants

Study Classification

INTERVENTIONAL

Study Start Date

2011-09-30

Study Completion Date

2017-03-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this research study is to determine if the addition of dutasteride to a regimen with abiraterone acetate and prednisone will improve on therapy in patients with castrate-resistant prostate cancer and metastatic disease. This study will also help determine the side effects of the study treatment and how often they occur.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Study of Abiraterone Acetate Without Exogenous Glucocorticoids in Men With Castration-resistant Prostate Cancer

NCT02025010

Castration-resistant Prostate Cancer

COMPLETED PHASE2

Abiraterone Acetate in Combination With Docetaxel After Disease Progression to Abiraterone Acetate in Metastatic Castration Resistant Prostate Cancer.

NCT02036060

Metastatic Prostate Cancer

COMPLETED PHASE2

Sequencing Abiraterone and Enzalutamide in mCRPC

NCT02125357

Metastatic Castration-Resistant Prostate Cancer

COMPLETED PHASE2

Abiraterone Acetate for Castrate Resistant Prostate Cancer

NCT01961843

Prostate Cancer

COMPLETED NA

Abiraterone Acetate and Prednisone With or Without Dasatinib in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

NCT01685125

Hormone-resistant Prostate Cancer Recurrent Prostate Cancer Stage IV Prostate Cancer

UNKNOWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Patients will receive abiraterone acetate and prednisone orally, once daily for 2 months (2 cycles) on an outpatient basis. At the start of cycle 3, dutasteride will be taken once daily. Patients will return to the clinic on Day 14 of the first 3 cycles for routine blood tests.

Patients will come to the clinic every 12 weeks for a CT scan and/or x-ray of the chest, CT scan or MRI of the abdomen and pelvis, bone scan, and blood test for testosterone and other specialized blood test.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Abiraterone+prednisone+dutasteride

Abiraterone acetate 1000mg orally once per day + prednisone 5mg orally once per day for two months, followed by abiraterone 1000mg orally once per day + prednisone 5mg orally once per day + dutasteride 3.5mg orally once per day in 28-day cycles until symptomatic or radiographic progression

Group Type EXPERIMENTAL

Abiraterone acetate

Intervention Type DRUG

Dutasteride

Intervention Type DRUG

Prednisone

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Abiraterone acetate

Intervention Type DRUG

Dutasteride

Intervention Type DRUG

Prednisone

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

CB7630 Avodart Corticosteroid

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Diagnosis of adenocarcinoma of the prostate
* Castrate resistant disease
* Metastatic disease
* Normal organ and marrow function
* Subjects with partners of childbearing potential must be willing to use adequate methods of birth control

Exclusion Criteria

* Uncontrolled intercurrent illness
* Uncontrolled hypertension
* Active or symptomatic viral hepatitis or chronic liver disease
* History of pituitary or adrenal dysfunction
* Clinically significant heart disease
* History of a different malignancy unless disease-free for at least 5 years
* Known brain metastasis
* History of gastrointestinal disorders
* Prior therapy with abiraterone acetate
* HIV-positive individuals on antiretroviral therapy
* Requirement for steroid use greater than the equivalent of 5 mg of prednisone daily
* Atrial fibrillation or other cardiac arrhythmia requiring therapy
* Thromboembolism in the last 6 months

Minimum Eligible Age

18 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

No